Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab

医学 无容量 内科学 肿瘤科 头颈部癌 头颈部鳞状细胞癌 无进展生存期 接收机工作特性 癌症 临床终点 免疫组织化学 对数秩检验 PD-L1 生存分析 胃肠病学 总体生存率 免疫疗法 临床试验
作者
Isaku Okamoto,Hiroki Sato,Kiyoaki Tsukahara
出处
期刊:Auris Nasus Larynx [Elsevier BV]
卷期号:47 (4): 676-686 被引量:13
标识
DOI:10.1016/j.anl.2020.04.001
摘要

Objective Our facility measures programmed cell death ligand 1 (PD-L1) expression in all patients before administering nivolumab. The aim of the present study is to clarify the association between overall survival (OS) and PD-L1 expression. Patients and Methods Subjects in this study were 52 patients with R/M-HNC cancer (45 men, 7 women) administered nivolumab in our facility between June 1, 2017 and January 31, 2019. Mean age was 62.2 years (median, 65 years; range, 28–81 years). Histopathological type was squamous cell carcinoma (SCC) in 48 cases, and non-SCC in 4 cases. We set OS as the primary endpoint and progression-free survival (PFS), overall response rate (ORR), association of OS and PD-L1 expression and association of PFS and PD-L1 expression as secondary endpoints. The cut-off for PD-L1 expression was set using the receiver operating characteristic (ROC) curve. We compared OS, PES and ORR using this PD-L1 cut-off for all patients and for the SCC group. OS and PFS were calculated using Kaplan-Meier methods. The log-rank test was used for statistical analysis, with values of p < 0.05 taken as significant. For PD-L1 immunohistochemistry assays, Dako 28-8 antibody was used. Results In the all-patients group, median OS was 9.6 months and 1-year OS rate was 40.4%. Median PFS was 4.0 months and 1-year PFS rate was 37.8%. The cut-off value of PD-L1 expression for OS was 40% for all patients and the SCC group. When PD-L1 expression was ≥40%, OS was significantly better in both all patients and the SCC group (p = 0.004, 0.007). The cut-off value of PD-L1 expression for PFS was also 40%. When PD-L1 expression was ≥40%, PFS was better in all patients and the SCC group (P = 0.003, 0.009). In the all-patients group, ORR was 19.2% and disease control rate (DCR) was 44.2%. When PD-L1 expression was ≥40%, ORR was 44.4% and DCR 83.3%. Conclusion In the present study, when PD-L1 expression was high (≥40%), OS was significantly better (p = 0.004). This finding has not been reported in other research on R/M-HNC. PFS and ORR were also better with high PD-L1 expression. Regarding patterns of progression with a PD-L1 expression cut-off of 40%, hyperprogression was significantly more frequent for PD-L1 expression <40% (p = 0.039). Therefore, high PD-L1 expression could offer a predictor of prognosis and efficacy for nivolumab. The present findings may prove useful in considering treatment strategies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
景景景发布了新的文献求助10
刚刚
眼睛大的傲菡完成签到,获得积分10
1秒前
anyon完成签到,获得积分10
1秒前
1秒前
li完成签到,获得积分10
2秒前
2秒前
木子发布了新的文献求助10
3秒前
钟嘉霖完成签到,获得积分10
3秒前
小小发布了新的文献求助100
4秒前
Maestro_S的应助被Kenny采纳,获得10
4秒前
天际小山完成签到,获得积分10
6秒前
6秒前
xing发布了新的文献求助10
6秒前
7秒前
丁鹏笑完成签到 ,获得积分0
7秒前
孟昊如完成签到,获得积分10
7秒前
null的应助被aaa采纳,获得10
8秒前
9秒前
11秒前
英姑的应助被aoa采纳,获得10
12秒前
13秒前
13秒前
清汐完成签到 ,获得积分10
13秒前
那当然完成签到 ,获得积分10
14秒前
14秒前
苗浩阳完成签到,获得积分10
16秒前
Shirley发布了新的文献求助10
17秒前
ChaseY完成签到 ,获得积分10
18秒前
xing发布了新的文献求助10
18秒前
科目三的应助被sinmon采纳,获得10
19秒前
WK完成签到,获得积分10
19秒前
20秒前
执着的青烟完成签到,获得积分10
20秒前
20秒前
20秒前
ice完成签到 ,获得积分10
21秒前
舔舔给舔舔的求助进行了留言
21秒前
22秒前
22秒前
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160961
求助须知:如何正确求助?哪些是违规求助? 9555819
关于积分的说明 21730291
捐赠科研通 7750940
什么是DOI,文献DOI怎么找? 3427477
关于科研通互助平台的介绍 2552515
邀请新用户注册赠送积分活动 2471912